Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

Clinical trial NCT07188012 · RECRUITING

Trial details

NCT number: NCT07188012
Sponsor: Shanghai Siponuoyin Biotechnology Co Ltd
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Duchenne Muscular Dystrophy (DMD)

Start date: 2025-08-06
Primary completion: 2026-12-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.